促红血球生成素刺激剂市场：现况分析与预测（2023-2030）

Erythropoietin Stimulating Agents Market: Current Analysis and Forecast (2023-2030)

出版日期: 2024年01月30日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 158 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

促红血球生成素兴奋剂 (ESA) 是刺激红血球生成的药物。它特别用于治疗慢性肾臟病和癌症引起的贫血。 ESA 模仿促红血球生成素的作用，促红血球生成素是一种在肾臟中产生的激素，可刺激骨髓中红血球的产生。然而，由于存在血液凝固增加和血压升高等潜在风险，其使用需要仔细监测。其他几个因素正在推动促红血球生成素兴奋剂的发展，包括越来越多的慢性肾臟病患者和导致贫血的不健康生活习惯。根据美国国立卫生研究院 2022 年 9 月的一项研究，过度吸烟和饮酒等生活方式选择与铁代谢相关，并被视为贫血的危险因子。此外，根据BMC 公共卫生局2023 年7 月的数据，不健康生活方式的盛行率分别为86.4% 的饮食、14.5% 的酒精、6.0% 的烟草、72.2% 的体力活动、42.3% 的萤幕时间和63.9% 的睡眠时间。

由于烟酒被认为是贫血的危险因素，全球盛行率不断上升，促红血球生成素兴奋剂市场预计将维持约8.6%的稳定成长。根据 2021 年全国药物使用与健康调查 (NSDUH)，2020 年有 2,950 万名 12 岁及以上的人患有酒精使用障碍 (AUD)。在预测期内，有几个因素正在推动市场成长，例如癌症发病率急剧上升、对贫血的认识不断提高以及医疗保健领域投资的增加。例如，根据切萨皮克肿瘤血液学协会研究的数据，到 2022 年 10 月，超过 62% 的转移性乳癌患者出现贫血。除此之外，促红血球生成素刺激剂治疗效率的加速导致治疗过程更快、准确性更高，这也稳定推动促红血球生成素刺激剂市场的发展。

依产品类型，市场分为依泊汀阿尔法、依泊汀贝塔、达贝泊汀阿尔法等。在全球促红血球生成素兴奋剂市场中，促红血球生成素-ALPHA细分市场占据最大份额。阿尔法依泊汀可增加红血球生成并提高血液中的含氧量，因此该细分市场占据了市场主导地位。阿尔法依泊汀是促红血球生成素的合成製剂，促红血球生成素是一种刺激红血球生成的荷尔蒙。它用于治疗贫血，特别是肾衰竭患者或接受化疗等某些治疗的患者。癌症发生率的增加正在推动这一领域的发展。例如，根据世界卫生组织 (WHO) 的数据，2020 年，全球有 230 万名女性被诊断出罹患乳癌，其中 68.5 万人死亡。因此，在产品类型中，Epoetin Alfa细分市场在2022年占据了重要的市场份额。

依适应症，市场分为肿瘤学、血液学、肾臟疾病等。由于肾臟疾病盛行率不断上升，预计肾臟疾病领域在预测期内将占据相当大的市场。例如，根据美国国家糖尿病、消化和肾臟疾病研究所的数据，美国有近 808,000 人患有末期肾病 (ESRD)。在因慢性肾臟疾病受损的肾臟中，促红血球生成素的产生减少，这会影响身体製造红血球的能力。肾臟疾病会破坏身体调节铁的能力并导致缺铁性贫血。研究和开发活动的增加也推动了该领域的发展。因此，在这些适应症中，肾臟疾病类别预计在预测期内表现出较高的复合年增长率。

为了更了解促红血球生成素兴奋剂的市场介绍，将市场分为北美（美国、加拿大等北美地区）、欧洲（德国、英国、法国、西班牙、义大利等欧洲地区）、亚太地区（中国、日本、印度、亚太地区其他地区）和世界其他地区。在目前的 2022 年情境中，由于酒精消费增加导致慢性肾臟损伤，以及开发有效促红血球生成素兴奋剂的研发和投资增加，北美将主导市场。例如，2023年9月，美国H. Lee Moffitt癌症中心和研究所研究了canakinumab联合darbepoetin alfa对既往促红血球生成素治疗失败的低风险MDS患者的毒性和毒性（ ESA）。我们已经开始了一项临床试验来评估疗效。政府机构已启动贫血意识计划，为患者提供有效的治疗。因此，从地区来看，2022年北美将占据较大的市场份额。

参与市场的主要公司包括F. Hoffmann-La Roche Ltd.、Pfizer Inc.、Thermo Fisher Scientific Inc.、Amgen Inc.、Biocon、Johnson &Johnson Services, Inc.、Teva Pharmaceutical Industries Ltd.、3SBio Group、CELLTRION INC.、Intas Pharmaceuticals Ltd.、Teva Pharmaceutical Industries Ltd.。

Erythropoietin-stimulating agents (ESAs) are medications that stimulate the production of red blood cells. They're often used to treat anemia, especially in conditions like chronic kidney disease or cancer. ESAs mimic the action of erythropoietin, a hormone produced by the kidneys that stimulates red blood cell production in the bone marrow. However, their usage requires careful monitoring due to potential risks, such as increased blood clotting or higher blood pressure. Several other factors, such as rising cases of chronic kidney disorders and unhealthy lifestyles which lead to anemia are leading drivers of erythropoietin-stimulating agents globally. According to the National Institute of Health's study in September 2022, lifestyle choices such as heavy cigarette smoking and alcohol consumption are found to be correlated with iron metabolism and seen as risk factors for anemia. Also, according to the BMC Public Health, in July 2023, the prevalence of unhealthy lifestyles was 86.4% for diet, 14.5% for alcohol, 6.0% for tobacco, 72.2% for physical activity, 42.3% for screen time, and 63.9% for sleep duration.

The Erythropoietin Stimulating Agents Market is expected to grow at a steady rate of around 8.6% owing to the increased prevalence of alcohol and tobacco globally which are seen as risk factors for anemia. According to the 2021 National Survey on Drug Use and Health (NSDUH), 29.5 million people ages 12 and older had Alcohol Use Disorder (AUD) in the year 2020. Several factors, including a surge in the incidence of cancer, increasing awareness regarding anemia, and increased investments in healthcare departments are driving the growth of the market during the forecast period. For instance, in October 2022, according to Chesapeake Oncology Hematology Associates Research, over 62% of patients with metastatic breast cancer developed anemia. Apart from this, accelerated treatment efficiency with erythropoietin stimulating agents has resulted in faster treatment procedures and better accuracy which is also driving this market of erythropoietin stimulating agents at a steady rate.

Based on product type, the market is segmented into epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. The epoetin-alfa segment held the maximum share in the global market of erythropoietin-stimulating agents 2022. This segment dominated the market because it helped increase red blood cell production, improving oxygen levels in the blood. Epoetin alfa is a synthetic form of erythropoietin, a hormone that stimulates the production of red blood cells. It's used to treat anemia, particularly in patients with kidney failure or those undergoing certain treatments like chemotherapy. Growing incidences of cancer are driving this segment. For instance, according to the World Health Organization in 2020, there were 2.3 million women diagnosed with breast cancer and 685,000 deaths globally. Thus, amongst product types, the epoetin-alfa segment held a significant market share in 2022.

Based on indication, the market is categorized into oncology, hematology, renal diseases, and others. The renal diseases segment is expected to hold a significant share of the market in the forecast period owing to the rising incidences of kidney disorders. For instance, according to the National Institute of Diabetes and Digestive and Kidney Diseases, nearly 808,000 people in the U.S. are living with end-stage renal disease (ESRD). Damaged kidneys in chronic kidney disease may produce less erythropoietin, impacting the body's ability to create red blood cells. Kidney disease can disrupt the body's ability to regulate iron, leading to iron deficiency anemia. This segment is also propelled by rising research and development activities. Thus, amongst indications, the renal diseases category is expected to witness higher CAGR during the forecast period.

For a better understanding of the market adoption of erythropoietin stimulating agents, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the increasing alcohol consumption leading to chronic kidney disorders, and the rising number of research and investments in developing effective erythropoietin-stimulating agents. For instance, in September 2023, U.S-based H. Lee Moffitt Cancer Center and Research Institute initiated a clinical trial for evaluating the toxicity and efficacy of canakinumab in combination with darbepoetin alfa in patients with lower-risk MDS who have failed prior treatment with an Erythropoietin Stimulating Agent (ESA). Government organizations are initiating anemia awareness programs to provide efficient care to patients. Thus, amongst regions, North America held a significant share of the market in 2022.

Some of the major players operating in the market include F. Hoffmann-La Roche Ltd.; Pfizer Inc.; Thermo Fisher Scientific Inc.; Amgen Inc.; Biocon; Johnson & Johnson Services, Inc.; Teva Pharmaceutical Industries Ltd.; 3SBio Group; CELLTRION INC.; Intas Pharmaceuticals Ltd.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Erythropoietin Stimulating Agents Market
2.2. Research Methodology of the Erythropoietin Stimulating Agents Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE ERYTHROPOIETIN STIMULATING AGENTS MARKET

6 ERYTHROPOIETIN STIMULATING AGENTS MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY PRODUCT TYPE

7.1. Epoetin-alfa
7.2. Epoetin-beta
7.3. Darbepoetin-alfa
7.4. Others

8 MARKET INSIGHTS BY INDICATION

8.1. Oncology
8.2. Haematology
8.3. Renal Diseases
8.4. Others

9 MARKET INSIGHTS BY REGION

9.1. North America
- 9.1.1. U.S.
- 9.1.2. Canada
- 9.1.3. Rest of North America
9.2. Europe
- 9.2.1. Germany
- 9.2.2. U.K.
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
9.3. Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Rest of Asia-Pacific
9.4. Rest of World